Cytokine levels in malignant ascites and peripheral blood of patients with advanced ovarian cancer;ZYTOKINSPIEGEL IM MALIGNEN ASZITES UND PERIPHEREN BLUT VON PATIENTINNEN MIT FORTGESCHRITTENEM OVARIALKARZINOM

Geburtshilfe und Frauenheilkunde

Volumn 56, Issue 2, 1996, Pages 83-87

  Radke, Jacqueline ^a,e   Schmidt, Doris ^b   Bohme M ^c   Schmidt, U ^d   Weise, W ^a   Morenz, J ^b  

^a Universitätsfrauenklinik   (Germany)

^b Institut fur Immunologie   (Germany)

^c Krankenhaus St Marienstift GmbH   (Germany)

^d OTTO VON GUERICKE UNIVERSITY   (Germany)

^e UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 6; INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; ASCITES; BLOOD ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; OVARY CANCER;

EID: 0029981673     PISSN: 00165751     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-1022247     Document Type: Article

References (27)

1. Andus, T., J. Bauer, W. Gerok: Effect of cytokines on the liver. Hepatology 13 (1991) 364-375.
2. Andus, T., K.-D Palitzsch, V Gross et al.: Metabolische und endokrine Funktionen der Zytokine. Dtsch. med. Wschr. 118 (1993) 306-313.
3. Andus, T., V. Gross, A. Holstege: High interleukin-6 concentrations in hepatic ascites Dig. Dis. Sci 39 (1994) 219-220.
4. Badger, A M., S. K. Oh, F. R. Moolten: Differential effects of an immunosuppressive fraction from ascites fluid of patients with ovarian cancer on spontaneous and antibody-dependent cytotoxicity. Cancer Res. 41 (1981) 1133-1139.
5. Baggiolini, M., I Clark-Lewis: Interleukin-8, a chemotactic and inflammatory cytokine. Febs Letters 307 (1992) 97-101.
6. Barton, D. P. J., D. K. Blanchard, B. Michelini-Norris et al.: High serum and ascites soluble interleukin-2 receptor α levels in advanced epithelial ovarian cancer. Blood 81 (1993) 424-429.
7. Barton, D. P. J., D. K. Blanchard, B. Michelini-Norris et al.: Serum soluble interleukin-2 receptor a levels in patients with gynecologic cancers: Early effect of surgery. Am. J. Reprod. Immunol. 30 (1993) 202-206.
8. Berek, J. S., R. C. Bast, A. Lichtenstein et al.: Lymphocyte cytotoxicity in the peritoneal cavity and blood of patients with ovarian cancer. Obstet. Gynecol. 64 (1984) 708-714.
9. Bogdan, C., Y. Vodovotz, C. Nathan: Macrophage deactivation by IL-10. J. Exp. Med. 174 (1991) 1549-1555.
10. Chouaib, S., J. Bertoglio, J.-Y. Blay et al.: Generation of lymphokine-activated killer cells: Synergy between tumor necrosis factor and interleukin-2. Proc. Natl. Sci. 85 (1988) 6875-6879.
11. Clemens, M J.: Cytokines. In Read. A. P., T. Brown (Hrsg.): The medical perspectives series. BIOS Scientific Publishers Limited. Oxford 1991 (85-92).
12. Fiorentino, D. F., A. Zlotnik, T. R. Mosmann et al : IL-10 inhibits cytokine production by activated macrophages. J. Immunol. 147 (1991) 3815-3822.
13. Friedlander, M. A., J. R. L. de Mola, J. M. Goldfarb: Elevated levels of interleukin-6 in ascites and serum from women with ovarian hyperstimulation syndrome. Fertil. Steril. 60 (1993) 826-833.
14. Friemel, H.: Zytokine. Faktoren der interzellulären Kommunikation. Immuno. Biological Laboratories, Hamburg (1992).
15. Gotlieb, W. H., J. S. Abrams, J. M. Watson et al.: Presence of interleukin 10 (IL-10) in the ascites of patients with ovarian and other intra-abdominal cancers. Cytokine 4 (1992) 385-390.
16. Heinrich, P. C., J. V. Castell, T. Andus: Interleukin-6 and the acute phase response. Biochem. J. 265 (1990) 621-636.
17. Karck, U., H. G. Meerpohl, A. Pfleiderer, H. P. Zahradnik: Ergebnisse nach TNF-Therapie von Patientinnen mit Ascites oder Pleuraerguß infolge von progredienten gynäkologischen Malignomen. In Hickl, E.-J., D. Berg (Hrsg.): Archives of Gynecology and Obstetrics. Springer-Verlag, New York Inc., 1991 (286-288).
18. Kaufmann, M., H. Schmidt U. Raeth et al.: Aszites-Therapie mit Tumornekrosefaktor beim Ovarialkarzinom. Geburtsh. u. Frauenheilk. 50 (1990) 678-682
19. Mantovani, A., C. Sessa, G. Peri et al.: Intraperitoneal administration of Corynebacterium parvum in patients with ascitic ovarian tumors resistant to chemotherapy: Effects on cytotoxicity of tumor-associated marcrophages and NK cells. Int. J. Cancer 27 (1981) 437.
20. Old, L. J.: Tumor necrosis factor and related cytotoxins. CIBA Foundation Symposium 131. John Wiley & Sons, New York (1987).
21. Plante, M., S. C. Rubin, Y. G. Wong et al.: IL-6 levels in ascites as a prognostic factor in patients with epithelial ovarian cancer. Selected Abstracts on Hematopoietic Growth Factors for Oncologists. 29th Annual Meeting of the American Society of Clinical Oncology, Orlando, Florida (1993) 47.
22. Plante, M., S. C. Rubin, G. Y. Wong et al.: Interleukin-6 level in serum and in ascites as a prognostic factor in patients with epithelial ovarian cancer. Cancer 73 (1994) 1882-1888.
23. Radke, J., D. Schmidt, M. Böhme et al.: Leukozyten- und Lymphozytenpopulationen im peripheren Blut und malignen Aszites von Patientinnen mit Ovarialkarzinom. Geburtsh. u. Frauenheilk. 54 (1994) 675-678.
24. Ramila, P., L. B. Epstein: Tumor necrosis factor as immunomodulator and mediator of monocyte eytotoxicity induced by itself, γ Interferon and interleukin-1. Nature 323 (1986) 86-89.
25. Taga, T., T. Kishimoto: Interleukin-6. In Aggarwal, B. B., J U. Gutterman (Hrsg.): Human Cytokines. Handbook of basic and clinical research. Blackwell Scientific Publications, Boston 1992 (143-167).
26. Watson, J. M., J. L Sensintaffar, J. S. Berek et al: Constitutive production of interleukin 6 by ovarian cancer cell lines and primary ovarian tumor cultures. Cancer Res. 50 (1990) 6959-6965.
27. de Waal Malefyt, R., J. Haanen, II. Spits et al.. Interleukin 10 (1L-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J. Exp. Med. 174 (1991) 915-924.